CBD LIFE SCIENCES INC - CBDL STOCK NEWS

CBD Life Sciences (OTC PINK: CBDL) has announced the launch of its new Green Apple Infused Gummies, featuring 15MG of Delta-8 and 10MG of Delta-9 per gummy. This product reflects the company's commitment to innovation and aims to enhance consumers' focus and mental well-being. Available in stores and soon on the LBC website, these gummies are rigorously tested for quality. The company, led by President & CEO Lisa Nelson, emphasizes its ongoing dedication to product development and shareholder updates through various online platforms.

CBD Life Sciences (OTC PINK:CBDL) announced the launch of its Delta-8 infused snacks through its subsidiary, LBC Bioscience Inc. The snacks come in five varieties, each containing 500MG of Delta-8. This legal cannabinoid is gaining popularity due to its mild psychoactive effects and potential therapeutic benefits. The company aims to maintain a competitive edge by using high-quality ingredients. The CBD market is projected to grow significantly, reaching USD 55.79 billion by 2028, indicating strong demand for cannabinoid products.

CBD Life Sciences (OTC PINK: CBDL) has launched a new laboratory operation at its retail location, CBD Vault, through its subsidiary, LBC Bioscience Inc. This initiative comes in response to increased demand, enabling production of a wide range of products, including tinctures and gummies. CEO Lisa Nelson highlighted that the new ultramodern machinery has quadrupled product development, allowing for large orders and innovations in product offerings. The global CBD market is projected to grow significantly, further driving opportunities for CBDL as consumer interest in therapeutic applications rises.

CBD Life Sciences (OTC PINK: CBDL) is preparing to attend the White Label Expo in Las Vegas from May 25-26, 2022. LBC Bioscience Inc., a subsidiary of CBD Life Sciences, aims to showcase their products and establish connections with key distributors. CEO Lisa Nelson noted the significant revenue generated during their previous participation, highlighting the expo's potential for growth. The event will host over 300 exhibitors and offer insights into innovative techniques and technologies in the industry.

CBD Life Sciences (OTC PINK: CBDL) announced the launch of new Delta-9 Gummies through its subsidiary, LBC Bioscience Inc. The gummies feature a 2:1 blend of CBD and Delta-9, offering 200MG of Delta-9 and 400MG of CBD per serving. This product aims to provide a balanced and calming experience. Consumers can expect availability both in-store and on the LBC website soon. The company is also revamping its e-commerce platform for a better shopping experience. CEO Lisa Nelson expressed excitement about the product launch and future updates.

SCOTTSDALE, AZ / ACCESSWIRE / March 10, 2022 / CBD Life Sciences (OTC PINK:CBDL) is gearing up for the ERRL Cup Cannabis Event on March 12-13, 2022, in Mesa, Arizona. This premier event allows CBD Life Sciences to showcase its products to key industry players. CEO Lisa Nelson highlighted the positive revenue impact of participating in such events. CBD Life Sciences emphasizes the extensive benefits of CBD for various health issues. The company offers a range of products, including CBD Bath Bombs and Pain Creams, available through its online store.

CBD Life Sciences (OTC PINK:CBDL) announced the launch of its 300MG Vegan Gummies on Amazon by the end of this week through its subsidiary, LBC Bioscience Inc.. This product aims to expand the company’s presence in the growing eCommerce sector, which has seen significant growth due to global trends.

These gummies are marketed as eco-friendly, toxin-free, and beneficial for inflammation and sleep health. CBD Life Sciences seeks to attract a wider clientele, leveraging Amazon's vast user base.

CBD Life Sciences (OTC PINK: CBDL) announces the upcoming production of HHC products via its subsidiary, LBC Bioscience Inc., set to begin next week. HHC, a stable form of THC, is gaining traction as an alternative cannabinoid, known for benefits such as pain relief and mental clarity. CEO Lisa Nelson highlights the product's potential to aid chronic pain sufferers. The company aims to stay ahead in the competitive cannabinoid space, as it already offers a wide range of CBD products. LBC also promotes its online store and various product offerings.

CBD Life Sciences (OTC PINK:CBDL) announced strategic initiatives in a letter to shareholders. The company plans to acquire new retail locations and vending machines across the United States, citing strong initial revenue from its first vending machine in Tanger Outlets, AZ. CEO Lisa Nelson revealed ongoing efforts to establish a 20,000 sq ft indoor Hemp Facility and hinted at a potential partnership in cryptocurrency mining. Additionally, product expansion in Europe is anticipated by spring 2022. CBD Life Sciences aims to keep shareholders informed as the company grows.